Screener
Arcutis Biotherapeutics, Inc. ARQT Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $129.86M+59.3% | $105.4M+60.1% | $129.5M+81.5% | $99.22M+122% | $81.5M+164% | ||
| $10.94M+46.0% | $9.78M+10.8% | $11.69M+69.3% | $8.69M+57.8% | $7.49M+116% | ||
| $118.92M+60.7% | $95.61M+67.7% | $117.82M+82.8% | $90.53M+131% | $74.01M+170% | ||
| 91.6%+0.8pp | 90.7%+4.1pp | 91%+0.7pp | 91.2%+3.5pp | 90.8%+2.0pp | ||
| $20.36M+4.6% | $30.63M+74.6% | $20.45M+41.2% | $19.6M+0.5% | $19.45M+0.8% | ||
| $82.14M+18.7% | $74.08M+15.7% | $78.98M+37.1% | $62.4M+6.1% | $69.17M+18.9% | ||
| $113.43M+18.0% | $114.49M+26.7% | $111.12M+40.7% | $90.69M+8.2% | $96.12M+18.8% | ||
| $16.43M+212% | -$9.09M+62.9% | —— | $8.53M+122% | -$14.61M+70.8% | ||
| 12.7%+30.6pp | -8.6%+28.6pp | —— | 8.6%+95.9pp | -17.9%+144pp | ||
| $3.41M+12.4% | $4.37M+46.5% | $3M-45.9% | $3.07M-53.8% | $3.03M-59.5% | ||
| -$1.28M-37.6% | -$20K-110% | —— | $2.04M-51.3% | -$933K-118% | ||
| $136K-60.2% | $93K-66.7% | $470K+45.5% | $80K— | $342K— | ||
| $15.01M+194% | -$11.3M+54.9% | —— | $7.41M+118% | -$15.89M+69.6% | ||
| 11.6%+31.0pp | -10.7%+27.3pp | —— | 7.5%+100pp | -19.5%+150pp | ||
| $0.11+185% | -$0.09+55.0% | —— | $0.06+118% | -$0.13+69.0% | ||
| $16.99M+221% | -$8.53M+60.1% | —— | $9.09M+124% | -$14.05M+71.7% | ||
| 13.1%+30.3pp | -8.1%+24.4pp | —— | 9.2%+93.2pp | -17.2%+144pp | ||
| $16.43M+212% | -$9.09M+62.9% | —— | $8.53M+122% | -$14.61M+70.8% |
FAQ
- What is Arcutis Biotherapeutics, Inc.'s revenue?
- Arcutis Biotherapeutics, Inc. (ARQT) generated $464.0M in revenue over the trailing twelve months, up 76.1% year over year.
- Is Arcutis Biotherapeutics, Inc. profitable?
- Arcutis Biotherapeutics, Inc. is not currently profitable: it reported a net loss of $4.8M over the trailing twelve months, a -13.9% net margin.
- What are Arcutis Biotherapeutics, Inc.'s profit margins?
- Gross margin is 91.1% and operating margin is -12.0%, with a -13.9% net margin.
- What is Arcutis Biotherapeutics, Inc.'s earnings per share?
- Arcutis Biotherapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.05.
- Where does Arcutis Biotherapeutics, Inc.'s income statement data come from?
- Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
